Granite Investment Partners’s Axsome Therapeutics AXSM Stock Holding History

Granite Investment Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.6M	Sell	80,299 -4,595	-5%	-$794K	0.83%	29
2025 Q4	$15.5M	Sell	84,894 -3,664	-4%	-$512K	0.92%	24
2025 Q3	$10.8M	Sell	88,558 -39,968	-31%	-$4.5M	0.61%	59
2025 Q2	$13.4M	Sell	128,526 -10,193	-7%	-$1.08M	0.65%	56
2025 Q1	$16.2M	Buy	138,719 +47,070	+51%	+$5.36M	0.82%	41
2024 Q4	$7.75M	Buy	+91,649	New	+$8.43M	0.34%	98

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Investment Partners's AXSM Position: Q1 2026 in Review

Granite Investment Partners reduced its Axsome Therapeutics (AXSM) stake by 5.4% in Q1 2026, selling an estimated $794K and leaving 80,299 shares worth $13.6M. The position accounts for 0.83% of the portfolio, ranked #29.

Granite Investment Partners first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. The position peaked at $16.2M in Q1 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Granite Investment Partners held 80,299 shares of Axsome Therapeutics worth $13.6M as of Q1 2026.
Granite Investment Partners sold 4,595 Axsome Therapeutics shares in Q1 2026, an estimated $794K.
Axsome Therapeutics made up 0.83% of Granite Investment Partners's portfolio in Q1 2026, its #29 holding.
Granite Investment Partners first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
Granite Investment Partners's Axsome Therapeutics position peaked at $16.2M in Q1 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Granite Investment Partners's 13F filing for Q1 2026, filed 30 Apr 2026.